From humble beginnings in 1983, Sun Pharma has grown into a leading specialty generic company worldwide and the No. 1 pharmaceutical company in India. In the U.S., we are amongst the leading specialty generic companies and are ranked No. 2 in generic dermatology by prescriptions. We have a presence in 80 countries across emerging markets, with Brazil, Mexico, Russia, Romania, and South Africa being some of the key markets. We maintain a strong footprint across Western Europe, Canada, Australia, New Zealand, Israel and Japan.
Recent Posts
- Sun Pharma reports Q1FY26 results
- Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
- Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
- Sun Pharma Brings Back Its #SecondBirthDate Campaign on National Doctors’ Day
- Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board
Recent Comments